NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)

ZNTL Technical Analysis
As on 29th May 2024 ZNTL SHARE Price closed @ 11.62 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 21.99 & Strong Sell for SHORT-TERM with Stoploss of 20.89 we also expect STOCK to react on Following IMPORTANT LEVELS.


Open 11.50 Change Price %
High 11.83 1 Day -0.24 -2.02
Low 10.98 1 Week -0.45 -3.73
Close 11.62 1 Month -1.26 -9.78
Volume 644900 1 Year -7.84 -40.29
52 Week High 30.05 | 52 Week Low 9.84
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
FFIE 0.44 -62.39%
RSLS 0.28 33.33%
AAL 11.62 -13.54%
CRKN 0.09 -18.18%
LMDX 0.02 0.00%
ASTS 9.02 69.23%
KTRA 0.27 42.11%
PONO 1.72 2.38%
NKLA 0.50 -1.96%
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
ASTSW 2.95 147.90%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
BCAC 22.71 125.30%
CFFEW 0.11 120.00%
JCIC 22.08 116.68%
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
AUVI 0.05 -82.76%
ACAQ-UN 2.50 -73.49%
AXAS 0.03 -70.00%
FFIE 0.44 -62.39%
MILEW 0.06 -53.85%
LOTZW 0.01 -50.00%
GMBLW 0.01 -50.00%
FFIEW 0.03 -50.00%
Daily Charts
Intraday Charts
Whats New @
Free Analysis
ZNTL Important Levels Intraday
ZNTL Forecast June 2024
4th UP Forecast24.59
3rd UP Forecast20.43
2nd UP Forecast17.86
1st UP Forecast15.29
1st DOWN Forecast7.95
2nd DOWN Forecast5.38
3rd DOWN Forecast2.81
4th DOWN Forecast-1.35
ZNTL Weekly Forecast
4th UP Forecast17.63
3rd UP Forecast15.70
2nd UP Forecast14.51
1st UP Forecast13.32
1st DOWN Forecast9.92
2nd DOWN Forecast8.73
3rd DOWN Forecast7.54
4th DOWN Forecast5.61
ZNTL Forecast2024
4th UP Forecast53.82
3rd UP Forecast40.29
2nd UP Forecast31.92
1st UP Forecast23.56
1st DOWN Forecast-0.32
2nd DOWN Forecast-8.68
3rd DOWN Forecast-17.05
4th DOWN Forecast-30.58
ZNTL Other Details
Segment EQ
Market Capital 3592067840.00
Sector Healthcare
Industry Biotechnology
Offical website >
ZNTL Address
ZNTL Latest News
Your Comments and Response on Zentalis Pharmaceuticals Inc
ZNTL Business Profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York. Address: 530 Seventh Avenue, New York, NY, United States, 10018
2005-2023 All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service